KRAS and neoplasm: Further research into PDOs with engineered driver mutations in KRAS, TP53, and SMAD4 genes revealed the role of KRAS in cellular mechanisms that drive cholesterol biosynthesis and metabolism, processes known to promote tumor growth and apoptosis resistance.